bookmark abstract background method aim conclusion introduction method recruitment inclusion criterion exclusion criterion food allergy related quality life questionnaire faqlq non responder questionnaire nrq single dose oral food challenge ofc criterion positive ofc result blood test sample size estimation ethic patient safety discussion conclusion additional file competing interest author contribution author information acknowledgement detail reference zurzolo allergy asthma clinical immunology allergy asthma clinical immunology research open access peanut allergen threshold study pat validation eliciting dos using novel single dose challenge protocol giovanni zurzolo katrina allen steve taylor wayne shreffler joseph baumert mimi tang lyle gurrin michael mathai julie nordlee audrey dunngalvin jonathan hourihane abstract background eliciting dose peanut allergic reaction peanut allergic population peanut protein derived oral food challenge ofc use graded incremental dos administered fixed time interval individual patient threshold dos used generate population dose distribution curve using probability distribution determined important clinically validate dose predictive allergenic response unselected group peanut allergic individual method aim multi centre study involving three national level referral teaching centre cork university hospital ireland royal childrens hospital melbourne australia massachusetts general hospital boston study process continue run centre recruited participates respective centre total participant aged year recruited routine allergy appointment centre aim ass precision predicted using single dose peanut peanut protein form cookie validated food allergy related quality life questionnaire faqlq self administered prior ofc month challenge ass impact single dose ofc faql serological cell based vitro study performed conclusion validation threshold allergic reaction peanut allergic subject potential value public health measure single dose ofc based upon statistical dose distribution analysis past challenge trial promise efficient approach identify highly sensitive patient within given food allergic population keywords eliciting dose food allergy related quality life questionnaire faqlq single dose peanut threshold oral food challenge ofc voluntary incidental trace allergen labelling vital peanut allergen threshold study pat introduction eliciting dose peanut allergic reaction peanut allergic population timated peanut protein estimate derived statistical dose distribution pea nut allergic individual child adult correspondence mailto hourihane ucc hourihane ucc paediatrics child health university college cork ireland full list information available end article individual participated oral food challenge ofc protocol use graded incremental dos adminis tered short fixed time interval shown figure strong monotonic relationship dose proportion study participant reacting tual extrapolated dose always possible determine whether reaction occurred discrete threshold dose allergen alternatively result cumulative dose consumed allergic zurzolo licensee central ltd open access article distributed term creative common attribution license permit unrestricted use distribution reproduction medium provided original work properly cited zurzolo allergy asthma clinical immunology figure population dose distribution model peanut threshold adapted manuscript title clinical challenge data development allergen management threshold precautionary labeling food vital individual time reaction statistical method used model dose distribution peanut allergic population precise threshold dose known fall within defined dosing interval exact threshold value unknown since rived statistical dose distribution model peanut allergic population important clinically val idate dose predictive allergenic response unselected group peanut allergic individual issue importance stakeholder food allergy last year increasing num ber food manufacturer incorporated voluntary allergen precautionary statement advise aller gic consumer potential presence allergen using may contain allergen statement legis lated variable content around world regulatory threshold allergen labelling currently exist country exception japan switzerland voluntary industry led initiative use clinical threshold basis precautionary labelling decision based estimate derived multiple dosing food challenge although attempt improve labelling introduced country australia voluntary incidental trace allergen labelling vital still hampered vol untary currently considered lack credibility study aim ass precision pre dicted using single dose peanut peanut protein approximately peanut kernel challenge validate modelling used develop precautionary labelling criterion vital currently vital us peanut protein estimate reference dos addition study examine whether peanut allergic consumer tolerant amount time higher vital threshold thus suggesting partic ipants tolerant would exceedingly low probability would react chosen pragmatically allow study proceed recruitment achievable number peanut allergic individual provide sufficient statistical power validate accur acy population threshold distribution peanut allergic individual discussed detail validation study would required prohibitively large much expensive study contrast would feasible study subject react lower dos including feel important standardise approach international level since finding study consequence food manufacturing industry global level plan initiate study cently supported review large multidiscip linary european group may contribute improvement precautionary labelling threshold set use regulator manufacturer protect food allergic consumer zurzolo allergy asthma clinical immunology method recruitment multi centre study involving three teaching cen tres total participant recruited centre follow appointment department allergy respective centre inclusion criterion patient must meet following criterion enrolled study age year old demonstrate evidence peanut allergy defined either history unequivocal exposure including accidental typical acute allergic reaction within preceding year positive peanut spt sige positive oral food challenge peanut performed within year either open oral food challenge dbpcfc double blind placebo controlled food challenge peanut never ingested sensitisation peanut positive predictive value ppv clinical allergy peanut serum ige cap feia peanut spt wheal size within month single dose challenge exclusion criterion patient meeting following criterion cluded study family child consent participate medically unfit challenge according local unit ofc guideline protocol high fever unwell intercurrent illness objective sign acute allergic reaction oral corticosteroid within day prior challenge episode anaphylaxis cause week prior challenge use antihistamine within day oral food challenge asthma well controlled demonstrated fevi predicted best food allergy related quality life questionnaire faqlq validated faql questionnaire self administered prior ofc month challenge ass whether impact novel single dose ofc protocol similar routine diagnostic ofc figure additional file non responder questionnaire nrq aim administer non responder questionnaire nrq set question intended permit compari son basic demographic clinical allergy data choosing participate study partici pant additional file nrq devel oped similar nrq used osborne single dose oral food challenge ofc standard ofc administers multiple dos minute depending challenge protocol give single dose peanut taken isolation level predicted whole peanut pea nut protein form cookie consisting granu lated sugar brown sugar purpose wheat flour vegetable shortening salt baking soda peanut flour added level represents whole peanut equivalent whole peanut subject allergic cookie ingredient wheat peanut dose ministered food known tolerated challenge material shelf stable manufactured uni versity nebraska distributed participating clinic centre criterion positive ofc result objective criterion used validation since dose predicted basis challenge associated objective response objective criterion outlined sampson practall criterion validated healthnuts study criterion include urticaria perioral periorbital angioedema vomiting diarrhoea respiratory cardiovascular compromise including anaphylaxis rhinoconjuctivitis objective sign quantitated number site duration presence participant ofc often expect severe outcome following ingestion may manifest subjective symptom subjective symptom recorded used analysis reaction validate derived developed basis objective reac tions subjective symptom recorded include head ache dizziness bloating abdominal pain cramp muscle ache aching joint anxiety tension agitation prior agreed objective criterion positive ofc result objective sign occurring within hour ingestion objective sign recorded concurrent noncontact urticaria persisting least minute perioral periorbital angioedema rhinoconjunctivitis diarrhoea vomiting excluding gag reflex zurzolo allergy asthma clinical immunology informed consent yes quality life qol food allergy questionnaire participant subsequently found ineligible data destroy data non responder kept end study follow figure study design diagram assessed eligibility single dose ofc cookie blood test hr observation department discussion result principal investigator via information handout study phone call next day ensure late reaction qol food allergy questionnaire month challenge phone call remind participant qol non responder questionnaire end recruitment evidence circulatory respiratory compromise anaphylaxis persistent cough wheeze change voice stridor difficulty breathing collapse blood test blood sample taken peanut ponent analysis quantitative peanut specific ige fluoroenzyme immunoassay minute ofc estimated prevalence equal nominal value displayed table sample size corresponds lower confidence limit upper confidence limit implies population proportion may little half much double observed proportion calculation conservative since us sample size expected single centre three centre sample size estimation population proportion peanut allergic child react nominal dose peanut estimated separately three participating centre corresponding observed proportion participant based three proportion strong evidence null hypothesis proportion reacting three centre centre specific estimate reported otherwise proportion aggregated three centre serve single centre independent estimate confidence interval population proportion calcu lated using property binomial distribution example confidence interval sample size table projected confidence interval prevalence clinical reactivity peanut allergic child adult receiving dose whole peanut peanut protein sample size ranging sample size peanut allergic individual value target prevalence projected confidence interval zurzolo allergy asthma clinical immunology combined sufficiently accurate rule gross compatibility nominal observed propor tion participant reacting summary statistic used compare fea tures participant non participant reactor non reactor variable examined include clinical severity previous reaction age sex spt wheal size peanut component specific ige level multivariable logistic regression analysis used identify combination feature identify low dose reactor ethic patient safety study approved cork university hospital research ethic committee ecm royal childrens hospital human research ethic committee hrecapp massachusetts general hospital research ethic committee written informed par ental adolescent consent assent younger child recorded participation pat challenge external safety monitor appointed experienced allergist otherwise involved study related study study centre discussion estimation threshold dose allergic reaction peanut peanut allergic subject potential value public health measure use statistical dose distribution modelling based upon result low dose clinical challenge peanut allergic individual viewed strong approach estimation population threshold peanut however clinical determination individual threshold based upon graded incrementally increas ing challenge dos administered convenient time tervals sometimes short minute dos individual threshold dos frequently reported cumulative dos impossible claim dose fully assimilated adminis tration next dose allen used approach estimate population threshold peanut allergic population based upon challenge individual log normal dose distribution whole pea nut peanut protein since cumulative dos used evaluation individual challenge subsequent statistical dose distribution modelling portant validate peanut using single dose approach peanut best studied food allergen term low dose ofc date novel pat approach could adapted major food allergen proposed clinical study support statistically determined based upon population dose distribution modelling plan approach peanut allergic subject distinct geographical region varied permissive entry criterion analysis non participant address common criticism ofc study representative general peanut allergic popula tion subject volunteered peanut allergic subject food challenge highly selected may represent whole spectrum activity peanut peanut allergic subject strict requirement objective sign used determine case important subjective reaction known resolve routine ofc continued objective sign recorded peanut allergic patient usually advised avoid food labelled may contain peanut recent study madsen showed stood accepted clinician patient food pro ducers zero risk realistic attainable option however clinical risk communication specific may increase anxiety risk taking behaviour without increasing awareness confidence safety currently standard approach used manufacturer relation precautionary labelling may due part lack agreement among scientific community regarding clinically safe threshold level current study validates aid scientific medical community also manufacturing industry use quantita tive precautionary labelling backed sound scientific evidence establishment safe threshold level peanut allergic community pat study offer new clinical paradigm methodology regard assessing clinical risk current study may potentially define patient highly sensitive validated questionnaire assessing faql shown patient gain nearly much failed ofc passed ofc probably due decreased uncertainty next future reaction hypothesise individual family may also show improvement pat single dose challenge tangible impact could promote adoption pat single dose peanut challenge unit currently performing diagnostic ofc proposed clinical study support statistically determined based upon population dose distribution modelling peanut may show promise clinical validation allergenic food source sufficient threshold data available model population dose distribution eventually single dose diagnostic ofc using food allergen may adopted well clinician may able use pat single dose ofcs easier perform routine diagnostic ofc dbpcfc could contribute plex analysis risk clinician currently make zurzolo allergy asthma clinical immunology heuristic fashion varies practitioner cur rently clinician make value judgement whether believe child exquisitely sensitive food therefore advise regard avoiding trace amount allergen food food precautionary labelling single dose protocol replace current clin ical food challenge diagnosis food lergy would provide extra clinical information patient level risk could help inform consumer choice physician advice patient regarding precau tionary labelling project may offer practical way discern whether allergic patient safely ingest food label may contain trace although outcome would require collaboration food industry uniform adoption criterion use precautionary label proposed australian vital strategy conclusion pat single dose ofc based upon statistical dose distribution analysis past challenge trial promise efficient approach identify highly sensitive patient within given food allergic population peanut protocol described herein evaluate practi cality approach allow assessment safety validation originally statistically deter mined dose distribution analysis would major benefit study would serve inform gov ernments application transparent sensible approach use precautionary labelling also aid public health agency establishment approach allergen management protect vast majority food allergic consumer patient additional file additional file food allergy quality life questionnaire parent form year additional file food allergy quality life questionnairechild form year additional file food allergy quality life questionnaireteenager form year additional file peanut single dose study non participant questionnaire competing interest declares competing interest received speaker honorarium travel support stallergenes nutricia mead johnson pfizer astra zeneca msd received research funding danone stallergenes received speaker honorarium pfizer abbott danone declares competing interest adg declares competing interest author contribution made substantial contribution conception design revising manuscript local clinical study made substantial contribution development study design protocol made substantial contribution conception design manuscript devised original research concept others revised manuscript critically important intellectual content revised manuscript critically important intellectual content devised original research concept others revised manuscript critically important intellectual content contributed refinement study protocol review manuscript reviewed epidemiological study design proposed statistical analysis plan contributed writing revision paper contributed revision paper contributed drafting manuscript adg contributed study design contributed drafting revising manuscript lead clinical study developed original research concept made substantial intellectual contribution manuscript involved drafting giving final approval version published author read approved final manuscript author information giovanni zurzolo phd scholar funded victoria university professor katrina allen paediatric gastroenterologist funded viertel senior medical research followership steve taylor professor university nebraska lincoln director food allergy research resource program farrp food industry funded consortium supporting food company wayne shreffler chief pediatric allergy immunology mgh associate professor pediatrics harvard medical school joseph baumert assistant professor university nebraska lincoln director food allergy research resource program farrp prof mimi tang director department allergy immunology royal childrens hospital melbourne prof lyle gurrin senior lecturer biostatistics centre molecular environmental genetic analytic mega epidemiology prof michael mathai senior lecturer college health biomedicine victoria university julie nordlee work farrp university nebraska lincoln audrey dunngalvin lecturer clinical psychology ucc cork jonathan hourihane professor paediatrics child health ucc cork acknowledgement project funded food allergy research resource program farrp dean tey consultant paediatrician department allergy royal childrens hospital melbourne contribution manuscript murdoch childrens research institute supported funding victorian government operational infrastructure support program also victoria university providing funding publishing manuscript detail murdoch childrens research institute melbourne australia biomedical lifestyle disease unit school biomedical health science victoria university melbourne australia department allergy immunology royal childrens hospital melbourne australia university melbourne department paediatrics melbourne australia food allergy research resource program university nebraska lincoln nebraska food allergy centre centre immunology inflammatory disease massachusetts general hospital harvard medical school boston usa melbourne school population global health university melbourne melbourne australia paediatrics child health university college cork ireland received june accepted august published september reference allen remington baumert crevel houben brook taylor clinical challenge data development allergen management threshold precautionary labeling food vital allergy clin immun press taylor crevel rwr sheffield kabourek baumert threshold dose peanut risk characterization based upon published result challenge peanut allergic individual food chem toxicol taylor moneret vautrin crevel rwr sheffield morisset dumont threshold dose peanut risk characterization based upon zurzolo allergy asthma clinical immunology diagnostic oral challenge series peanut allergic individual food chem toxicol zurzolo mathai koplin allen precautionary allergen labelling following new labelling practice australia paediatr child health zurzolo koplin mathai mimi allen perception precautionary labelling among parent child food allergy anaphylaxis med aust epub allergen bureau summary vital scientific expert panel recommendation available downloads vital vsep summary report oct madsen hattersley allen beyer chan godefroy define tolerable level risk food allergy report europrevall food standard agency workshop clinical experimental allergy osborne koplin martin gurrin thiele tang healthnuts population based study paediatric food allergy validity safety acceptability clinical experimental allergy sampson gerth van wijk bindslev jensen sicherer teuber burk standardizing double blind placebo controlled oral food challenge american academy allergy asthma immunology european academy allergy clinical immunology practall consensus report allergy clin immun koplin tang mlk martin osborne lowe ponsonby predetermined challenge eligibility cessation criterion oral food challenge healthnuts population based study infant allergy clin immun dunngalvin hourihane developmental aspect health related quality life hrql food related chronic disease example food allergy handbook behavior food nutrition edited preedy watson martin new york springer dunngalvin hourihane job chapter developmental trajectory food allergy review advance food nutrition research edited steve waltham massachusetts usa academic press kruizinga briggs crevel rwr knulst bosch lmc houben probabilistic risk assessment model allergen food sensitivity analysis minimum eliciting dose food consumption food chem toxicol madsen hattersley buck gendel houben hourihane job approach risk assessment food allergy report workshop developing framework assessing risk allergenic food food chem toxicol mill enc valovirta madsen taylor vieths anklam information provision allergic consumer going food allergen labelling allergy marklund wilde larsson ahlstedt nordstrom adolescent experience food hypersensitive qualitative study bmc nurs epub hourihane job bedwani dean warner randomised double blind crossover challenge study allergenicity peanut oil subject allergic peanut bmj madsen crevel chan dubois aej dunngalvin flokstra blok bmj food allergy stakeholder perspective acceptable risk regul toxicol pharmacol dunngalvin cullinane daly flokstra blok bmj dubois aej hourihane job longitudinal validity responsiveness food allergy quality life questionnaire parent form child year following positive negative food challenge clinical experimental allergy dunngalvin gaffney hourihane job developmental pathway food allergy new theoretical framework allergy dunngalvin hourihane job self assessment reaction threshold food allergy new theory risk taking change time allergy clin immun cite article zurzolo peanut allergen threshold study pat validation eliciting dos using novel single dose challenge protocol allergy asthma clinical immunology submit next manuscript central take full advantage convenient online submission thorough peer review space constraint color gure charge immediate publication acceptance inclusion pubmed ca scopus google scholar research freely available redistribution submit manuscript www biomedcentral submit